# Teniposide, Cisplatin and Serplulimab for Treatment of ES-SCLC, a Randomized Controlled Study

Source: https://onco.cc/trials/nct07583511/  
OnCo record `nct07583511` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Teniposide, Etoposide, Serplulimab and Cisplatin in Small-cell lung cancer, run by Sun Yat-sen University, now recruiting.

## Summary

Teniposide, Cisplatin and Serplulimab for Treatment of ES-SCLC, a Randomized Controlled Study is a phase 2 interventional study registered as NCT07583511 by Sun Yat-sen University, with 90 participants planned, started 2024-02-01 and due to reach its primary completion in 2027-05-01. Interventions recorded: Teniposide, Etoposide, serplulimab, cisplatin. Conditions recorded: Small-cell Lung Cancer.

Linked to the drug Teniposide because the registry names it among its interventions and Small-cell lung cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07583511
- Phase: 2
- Setting: Comparison of Teniposide, Cisplatin and Serplulimab Regimen With Etoposide, Cisplatin and Serplulimab Regimen for Treatment of Extensive Stage Small Lung Cancer, a Random, Open Label, Positive Control, Multicenter Study
- Sponsor: Sun Yat-sen University
- Enrolled: 90

## Sources

- ClinicalTrials.gov NCT07583511: https://clinicaltrials.gov/study/NCT07583511

## Connected records

- cancers: [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Cisplatin](https://onco.cc/drugs/cisplatin/), [Etoposide](https://onco.cc/drugs/etoposide/), [Serplulimab](https://onco.cc/drugs/serplulimab/), [Teniposide](https://onco.cc/drugs/teniposide/)

---
JSON: https://onco.cc/api/v1/entities/nct07583511.json